Faculty
Oncology Division
Alphabetical list (active faculty):   
Mark A. Schroeder

Mark A. Schroeder, MD

Associate Professor

Department of Medicine

Oncology Division

Bone Marrow Transplantation & Leukemia

Clinical Interests

  • Hematologic malignancies including multiple myeloma
  • Hematopoietic stem cell transplantation
  • Transplant for sickle cell disease

Research Interests

  • Transplant biology
  • Graft-versus-host disease
  • Graft-versus-tumor effects
  • Stem cell mobilization

Contact

  • 314-454-8306 (office)
  • 314-362-9335 (lab)
  • 314-454-7551 (fax)
  • Division of Oncology
    Mail Stop 8007-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor Mid-Campus Center (office)

Original Articles

  • Systemic IL-15 Promotes Allogeneic Cell Rejection in Patients Treated With Natural Killer Cell Adoptive Therapy
    Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs MT, Wong P, Foster M, McClain E, Desai S, Pence P, Cooley S, Brunstein CG, Gao F, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein K, Schroeder MA, DiPersio JF, Soon-Shiong P, Miller JS, Fehniger TA
    Blood 2021 Nov 19; [Epub ahead of print]
  • A Single Center Retrospective Study of Daratumumab, Pomalidomide, and Dexamethasone as 2nd-Line Therapy in Multiple Myeloma
    Liu L, Fiala M, Gao F, King J, Goldsmith S, Wildes TM, Stockerl-Goldstein K, Vij R, Schroeder MA
    Leuk Lymphoma 2021 Dec;62(12):3043-3046
  • Combination of Dociparstat Sodium (DSTAT), a CXCL12/CXCR4 Inhibitor, With Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDS
    Huselton E, Rettig MP, Campbell K, Cashen AF, DiPersio JF, Gao F, Jacoby MA, Pusic I, Romee R, Schroeder MA, Uy GL, Marcus S, Westervelt P
    Leuk Res 2021 Nov;110:106713
  • Daratumumab for the Treatment of Multiple Myeloma
    Goldsmith SR, Foley N, Schroeder MA
    Drugs Today (Barc) 2021 Oct;57(10):591-605
  • Ruxolitinib Resistance or Intolerance in Steroid-Refractory Acute Graft-Versus-Host Disease - A Real-World Outcomes Analysis
    Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F, Grunwald MR, Butler C, Hamadani M
    Br J Haematol 2021 Nov;195(3):429-432
  • Maintenance Therapy After Second Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. A CIBMTR Analysis
    Pasvolsky O, Yeshurun M, Fraser R, Estrada-Merly N, Rozovski U, Shargian-Alon L, Assal A, Banerjee R, Bumma N, Gale RP, Hagen P, Holmberg L, Hossain NM, Lazarus HM, Lee C, Mian H, Miller KC, Nathan S, Nagler A, Nishihori T, Parrondo RD, Patel S, Schroeder MA, Usmani SZ, Wang T, Wirk B, Kumar S, Shah N, Qazilbash MH, D'Souza A
    Bone Marrow Transplant 2021 Oct 4; [Epub ahead of print]
  • A Phase 2a Randomized Clinical Trial of Intravenous Vedolizumab for the Treatment of Steroid-Refractory Intestinal Acute Graft-Versus-Host Disease
    Floisand Y, Schroeder MA, Chevallier P, Selleslag D, Devine S, Renteria AS, Mohty M, Yakoub-Agha I, Chen C, Parfionovas A, Quadri S, Jansson J, Akbari M, Chen YB
    Bone Marrow Transplant 2021 Oct;56(10):2477-2488
  • Machine Learning-Based Scoring Models to Predict Hematopoietic Stem Cell Mobilization in Allogeneic Donors
    Xiang J, Shi M, Fiala MA, Gao F, Rettig MP, Uy GL, Schroeder MA, Weilbaecher KN, Stockerl-Goldstein K, Mollah S, DiPersio JF
    Blood Adv 2021 Sep 23; [Epub ahead of print]
  • HLA-Haploidentical Vs Matched Unrelated Donor Transplants With Posttransplant Cyclophosphamide-Based Prophylaxis
    Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, Bredeson CN, Brunstein CG, Chhabra S, Fuchs EJ, Ghosh N, Grunwald MR, Kanakry CG, Kekre N, McGuirk JP, McNiece IK, Mehta RS, Mielcarek M, Milano F, Modi D, Reshef R, Solomon SR, Schroeder MA, Waller EK, Inamoto Y, Soiffer RJ, Eapen M
    Blood 2021 Jul 22;138(3):273-282
  • Autologous Stem Cell Transplant for Patients With Multiple Myeloma Between Ages 75 and 78
    Fiala MA, King J, Feinberg D, Goldsmith SR, Schroeder MA, Ghobadi A, Stockerl-Goldstein KE, Vij R, Wildes TM
    Bone Marrow Transplant 2021 Aug;56(8):2016-2018
  • Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia
    Barnell EK, Newcomer KF, Skidmore ZL, Krysiak K, Anderson SR, Wartman LD, Oh ST, Welch JS, Stockerl-Goldstein KE, Vij R, Cashen AF, Pusic I, Westervelt P, Abboud CN, Ghobadi A, Uy GL, Schroeder MA, Dipersio JF, Politi MC, Spencer DH, Duncavage EJ, Ley TJ, Griffith M, Jacoby MA, Griffith OL
    JCO Precis Oncol 2021 Jan 14;5:182
  • A Phase I Trial Evaluating the Effects of Plerixafor, G-CSF, and Azacitidine for the Treatment of Myelodysplastic Syndromes
    Huselton E, Rettig MP, Fletcher T, Ritchey J, Gehrs L, McFarland K, Christ S, Eades WC, Trinkaus K, Romee R, Kulkarni S, Ghobadi A, Abboud C, Cashen AF, Stockerl-Goldstein K, Uy GL, Vij R, Westervelt P, DiPersio JF, Schroeder MA
    Leuk Lymphoma 2021 Jun;62(6):1441-1449
  • Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations With Response After Adoptive Immunotherapy for Leukemia
    Berrien-Elliott MM, Cashen AF, Cubitt CC, Neal CC, Wong P, Wagner JA, Foster M, Schappe T, Desai S, McClain E, Becker-Hapak M, Foltz JA, Cooper ML, Jaeger N, Srivatsan SN, Gao F, Romee R, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein KE, Schroeder MA, DiPersio J, Fehniger TA
    Cancer Discov 2020 Dec;10(12):1854-1871
  • Insights Into the Role of the JAK/STAT Signaling Pathway in Graft-Versus-Host Disease
    Abboud R, Choi J, Ruminski P, Schroeder MA, Kim S, Abboud CN, DiPersio JF
    Ther Adv Hematol 2020 Jun 2;11:2040620720914489
  • Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Patients With Multiple Myeloma
    Fiala MA, Vosuri V, Goldsmith S, Schroeder MA, Ghobadi A, Wildes TM, Stockerl-Goldstein KE, Vij R
    Bone Marrow Transplant 2020 Jun;55(6):1188-1190
  • Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
    Saad A, de Lima M, Anand S, Bhatt VR, Bookout R, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Giralt S, Gutman J, Ho V, Horwitz M, Hsu J, Juckett M, Kharfan-Dabaja MA, Loren A, Meade J, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Roddy J, Satyanarayana G, Schroeder M, Tan CR, Tzachanis D, Burn J, Pluchino L
    J Natl Compr Canc Netw 2020 May 1;18(5):599-634
  • The Effect of Donor Type on Outcomes in Adults With Acute Myeloid Leukemia After Reduced-Intensity Hematopoietic Peripheral Blood Cell Transplant - A Retrospective Study
    Rashid N, Slade M, Abboud R, Gao F, DiPersio JF, Westervelt P, Uy G, Stockerl-Goldstein K, Romee R, Schroeder MA
    Transpl Int 2020 Sep;33(9):1089-1098
  • Ruxolitinib for the Treatment of Steroid-Refractory Acute GVHD (REACH1): A Multicenter, Open-Label Phase 2 Trial
    Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ
    Blood 2020 May 14;135(20):1739-1749
  • DCEP and Bendamustine/Prednisone as Salvage Therapy for Quad- and Penta-Refractory Multiple Myeloma
    Goldsmith SR, Fiala MA, Wang B, Schroeder MA, Wildes TM, Ghobadi A, Stockerl-Goldstein K, Vij R
    Ann Hematol 2020 May;99(5):1041-1048
  • A Phase 1 Trial of Itacitinib, a Selective JAK1 Inhibitor, in Patients With Acute Graft-Versus-Host Disease
    Schroeder MA, Khoury HJ, Jagasia M, Ali H, Schiller GJ, Staser K, Choi J, Gehrs L, Arbushites MC, Yan Y, Langmuir P, Srinivas N, Pratta M, Perales MA, Chen YB, Meyers G, DiPersio JF
    Blood Adv 2020 Apr 28;4(8):1656-1669
  • Ruxolitinib for Steroid-Refractory Acute Graft-Versus-Host Disease
    Toama W, Fiala MA, Pusic I, Westervelt P, DiPersio JF, Schroeder MA
    Transpl Int 2020 Feb;33(2):244-246
  • Selinexor Combined With Cladribine, Cytarabine, and Filgrastim in Relapsed or Refractory Acute Myeloid Leukemia
    Abboud R, Chendamarai E, Rettig MP, Trinkaus KM, Riedell PA, Abboud CN, Ghobadi A, Pusic I, Stockerl-Goldstein K, Schroeder MA, Vij R, Westervelt P, DiPersio JF, Uy GL
    Haematologica 2020 Aug;105(8):e404-e407
  • A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients With Relapsed/Refractory B-Cell Lymphoma
    Tuscano JM, Maverakis E, Groshen S, Tsao-Wei D, Luxardi G, Merleev AA, Beaven A, DiPersio JF, Popplewell L, Chen R, Kirschbaum M, Schroeder MA, Newman EM
    Clin Cancer Res 2019 Dec 1;25(23):7004-7013
  • EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms
    Goldsmith SR, Fiala MA, O'Neal J, Souroullas GP, Toama W, Vij R, Schroeder MA
    Clin Lymphoma Myeloma Leuk 2019 Nov;19(11):744-750
  • A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
    Ghobadi A, Fiala MA, Rettig MP, Schroeder MA, Uy GL, Stockerl-Goldstein KE, Westervelt P, Vij R, DiPersio JF
    Clin Lymphoma Myeloma Leuk 2019 Oct;19(10):e588-e593
  • Glasdegib for the Treatment of Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Grade Myelodysplastic Syndrome Who Are Elderly or Otherwise Unfit for Standard Induction Chemotherapy
    Goldsmith SR, Lovell AR, Schroeder MA
    Drugs Today (Barc) 2019 Sep;55(9):545-562
  • A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
    Schroeder MA, Fiala MA, Huselton E, Cardone MH, Jaeger S, Jean SR, Shea K, Ghobadi A, Wildes TM, Stockerl-Goldstein KE, Vij R
    Clin Cancer Res 2019 Jul 1;25(13):3776-3783
  • Next Generation Sequencing-Based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study
    Goldsmith SR, Fiala MA, Dukeman J, Ghobadi A, Stockerl-Goldstein KE, Schroeder MA, Tomasson M, Wildes TM, Vij R
    Clin Lymphoma Myeloma Leuk 2019 May;19(5):285-289
  • Glasdegib in Combination With Cytarabine and Daunorubicin in Patients With AML or High-Risk MDS: Phase 2 Study Results
    Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Naveed Shaik M, Douglas Laird A, O'Connell A, Chan G, Schroeder MA
    Am J Hematol 2018 Nov;93(11):1301-1310
  • Modeling Chronic Graft Versus Host Disease in Mice Using Allogeneic Bone Marrow and Splenocyte Transfer
    Schroeder MA, Ashami K, Staser K
    Curr Protoc Pharmacol 2018 Dec;83(1):e47
  • Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment
    Malecek MK, Fiala M, Schroeder M, Dukeman J, Ghobadi A, Stockerl-Goldstein K, Wildes T, Vij R
    Clin Lymphoma Myeloma Leuk 2018 Sep;18(9):e363-e364
  • A Multi-Center Phase I Trial of Ipilimumab in Patients With Myelodysplastic Syndromes Following Hypomethylating Agent Failure
    Zeidan AM, Knaus HA, Robinson TM, Towlerton AMH, Warren EH, Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, DeZern AE, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD
    Clin Cancer Res 2018 Aug 1;24(15):3519-3527
  • The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia
    Schroeder MA, Choi J, Staser K, DiPersio JF
    Biol Blood Marrow Transplant 2018 Jun;24(6):1125-1134
  • Transfer of Cell-Surface Antigens by Scavenger Receptor CD36 Promotes Thymic Regulatory T Cell Receptor Repertoire Development and Allo-Tolerance
    Perry JSA, Russler-Germain EV, Zhou YW, Purtha W, Cooper ML, Choi J, Schroeder MA, Salazar V, Egawa T, Lee BC, Abumrad NA, Kim BS, Anderson MS, DiPersio JF, Hsieh CS
    Immunity 2018 Jun 19;48(6):1271
  • CD36 Mediates Cell-Surface Antigens to Promote Thymic Development of the Regulatory T Cell Receptor Repertoire and Allo-Tolerance
    Perry JSA, Russler-Germain EV, Zhou YW, Purtha W, Cooper ML, Choi J, Schroeder MA, Salazar V, Egawa T, Lee BC, Abumrad NA, Kim BS, Anderson MS, DiPersio JF, Hsieh CS
    Immunity 2018 May 15;48(5):923-936e4
  • Baricitinib-Induced Blockade of Interferon Gamma Receptor and Interleukin-6 Receptor for the Prevention and Treatment of Graft-Versus-Host Disease
    Choi J, Cooper ML, Staser K, Ashami K, Vij KR, Wang B, Marsala L, Niswonger J, Ritchey J, Alahmari B, Achilefu S, Tsunoda I, Schroeder MA, DiPersio JF
    Leukemia 2018 Nov;32(11):2483-2494
  • Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination With Standard Chemotherapy in Patients With AML or High-Risk MDS
    Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE
    Clin Cancer Res 2018 May 15;24(10):2294-2303
  • Donor-Lymphocyte Infusion Following Haploidentical Hematopoietic Cell Transplantation With Peripheral Blood Stem Cell Grafts and PTCy
    Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Schroeder MA, Gao F, Romee R
    Bone Marrow Transplant 2017 Dec;52(12):1623-1628
  • Patterns of Infectious Complications in Acute Myeloid Leukemia and Myelodysplastic Syndromes Patients Treated With 10-Day Decitabine Regimen
    Ali AM, Weisel D, Gao F, Uy GL, Cashen AF, Jacoby MA, Wartman LD, Ghobadi A, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Schroeder MA, Westervelt P, DiPersio JF, Welch JS
    Cancer Med 2017 Dec;6(12):2814-2821
  • Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) Versus Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma and Non-Hodgkin Lymphoma
    Bhamidipati PK, Fiala MA, Grossman BJ, DiPersio JF, Stockerl-Goldstein K, Gao F, Uy GL, Westervelt P, Schroeder MA, Cashen AF, Abboud CN, Vij R
    Biol Blood Marrow Transplant 2017 Dec;23(12):2065-2069
  • Haploidentical Hematopoietic Cell Transplant With Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults With Acute Myeloid Leukemia or Myelodysplastic Syndrome
    Slade M, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Romee R
    Biol Blood Marrow Transplant 2017 Oct;23(10):1736-1743
  • Azacitidine Mitigates Graft-Versus-Host Disease Via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells in Vivo
    Cooper ML, Choi J, Karpova D, Vij K, Ritchey J, Schroeder MA, DiPersio JF
    J Immunol 2017 May 1;198(9):3746-3754
  • Mobilization of Allogeneic Peripheral Blood Stem Cell Donors With Intravenous Plerixafor Mobilizes a Unique Graft
    Schroeder MA, Rettig MP, Lopez S, Christ S, Fiala M, Eades W, Mir FA, Shao J, McFarland K, Trinkaus K, Shannon W, Deych E, Yu J, Vij R, Stockerl-Goldstein K, Cashen AF, Uy GL, Abboud CN, Westervelt P, DiPersio JF
    Blood 2017 May 11;129(19):2680-2692
  • A Proposed Biology- and Biomarker-Based Algorithm for Management of Acute GvHD
    Ali AM, DiPersio JF, Schroeder MA
    Bone Marrow Transplant 2017 Feb;52(2):337-340
  • T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation From Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia
    How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2017 Apr;23(4):648-653
  • Single Institution Experience With G-CSF Mobilized T-Cell Replete Haploidentical Hematopoietic Cell Transplantation
    Huselton E, Slade M, DiPersio JF, Westervelt P, Vij R, Uy GL, Fehniger TA, Abboud CN, Gao F, Schroeder MA, Romee R
    Bone Marrow Transplant 2017 May;52(5):769-771
  • TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ
    N Engl J Med 2016 Nov 24;375(21):2023-2036
  • Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Stem Cell Transplant
    Motabi IH, Ghobadi A, Liu J, Schroeder M, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Uy GL, Vij R, Westervelt P, DiPersio JF
    Biol Blood Marrow Transplant 2016 Jul;22(7):1324-9
  • Severe Cytokine-Release Syndrome After T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated With Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated
    Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, Meier S, Fehniger TA, Abboud CN, Uy GL, Vij R, Trinkaus KM, Schroeder MA, Romee R
    Biol Blood Marrow Transplant 2016 Oct;22(10):1851-60
  • Comparison of Outcomes After Peripheral Blood Haploidentical Versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia: A Retrospective Single-Center Review
    Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, Fehniger TA, Romee R
    Biol Blood Marrow Transplant 2016 Sep;22(9):1696-701
  • The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-Versus-Host Disease: A Systematic Review
    Ali AM, DiPersio JF, Schroeder MA
    Biol Blood Marrow Transplant 2016 Sep;22(9):1552-64
  • HLA Disparity Is Not Inconsequential in Peripheral Blood T-Replete Haploidentical Hematopoietic Stem Cell Transplantation
    Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Schroeder MA, Pusic I, Cashen AF, Fehniger TA, Romee R
    Bone Marrow Transplant 2016 Sep;51(9):1275-8
  • Phase I Study of Azacitidine Following Donor Lymphocyte Infusion for Relapsed Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation
    Ghobadi A, Choi J, Fiala MA, Fletcher T, Liu J, Eissenberg LG, Abboud C, Cashen A, Vij R, Schroeder MA, Pusic I, Stockerl-Goldstein K, Jacoby M, Uy G, DiPersio J, Westervelt P
    Leuk Res 2016 Oct;49:1-6
  • Cytomegalovirus Viremia, Disease, and Impact on Relapse in T-Cell Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide
    Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Dubberke ER, Trinkaus K, Romee R
    Haematologica 2016 Nov;101(11):e465-e468
  • Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-Versus-Host Disease After Mucotoxic Myeloablative Conditioning
    Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Schroeder MA, Cashen AF, Pusic I, Romee R
    Biol Blood Marrow Transplant 2016 Jun;22(6):1137-41
  • Hematologic Recovery After Pretransplant Chemotherapy Does Not Influence Survival After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients
    Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R
    Biol Blood Marrow Transplant 2015 Aug;21(8):1425-30
  • Do Somatic Mutations in De Novo MDS Predict for Response to Treatment?
    Schroeder MA, DeZern AE
    Hematology Am Soc Hematol Educ Program 2015 Dec 5;2015(1):317-28
  • A Phase I Dose Escalation Study of Oral Bexarotene in Combination With Intravenous Decitabine in Patients With AML
    Welch JS, Niu H, Uy GL, Westervelt P, Abboud CN, Vij R, Stockerl-Goldstein KE, Jacoby M, Pusic I, Schroeder MA, DiPersio JF, Cashen AF
    Am J Hematol 2014 Aug;89(8):E103-8
  • Haploidentical Transplantation Using G-CSF-Mobilized T-Cell Replete PBSCs and Post-Transplantation CY After Non-Myeloablative Conditioning Is Safe and Is Associated With Favorable Outcomes
    Bhamidipati PK, DiPersio JF, Stockerl-Goldstein K, Rashidi A, Gao F, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Keller JW, Fehniger TA, Romee R
    Bone Marrow Transplant 2014 Aug;49(8):1124-6
  • Protective Effect of Cytomegalovirus Reactivation on Relapse After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen
    Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R
    Biol Blood Marrow Transplant 2014 Jan;20(1):46-52
  • Mobilization of Hematopoietic Stem and Leukemia Cells
    Schroeder MA, Dipersio JF
    J Leukoc Biol 2012 Jan;91(1):47-57
  • Mouse Models of Graft-Versus-Host Disease: Advances and Limitations
    Schroeder MA, DiPersio JF
    Dis Model Mech 2011 May;4(3):318-33
  • Myelodysplastic Syndromes
    Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P
    J Natl Compr Canc Netw 2011 Jan;9(1):30-56
  • Evidence-Based Mini-Review: Should Patients Over the Age of 60 With INT-2 or High-Risk Myelodysplastic Syndrome Undergo Allogeneic Stem Cell Transplantation Prior to Progression to Acute Myelogenous Leukemia?
    Schroeder MA, Blum W
    Hematology Am Soc Hematol Educ Program 2010;2010:322-4